Side Effects of Olanzapine
Olanzapine causes common side effects including drowsiness, orthostatic hypotension, weight gain, and metabolic disturbances, with serious but less frequent risks of neuroleptic malignant syndrome, tardive dyskinesia, and potentially fatal respiratory depression when combined with benzodiazepines.
Common Side Effects
The most frequently encountered adverse effects with olanzapine include:
- Drowsiness/Sedation - occurs in approximately 25% of patients 1
- Weight gain - can be extreme and represents the most common significant problem with long-term use 2, 3
- Orthostatic hypotension - particularly during initial dose titration 1, 2
- Metabolic effects including hyperglycemia, dyslipidemia, and increased appetite (especially with long-term use) 1, 3
- Dry mouth, constipation, and increased appetite 3
- Anticholinergic effects 4
The FDA drug label specifically lists postural hypotension, constipation, weight gain, dizziness, personality disorder, and akathisia as common adverse reactions occurring at ≥5% frequency and at least twice that of placebo 3.
Serious Side Effects Requiring Immediate Action
Neuroleptic Malignant Syndrome (NMS)
This rare but potentially fatal condition requires immediate hospitalization. Watch for 3:
- High fever
- Excessive sweating
- Rigid muscles
- Confusion
- Changes in breathing, heartbeat, and blood pressure
Tardive Dyskinesia
Involuntary body movements, usually affecting the face and tongue, that may not resolve even after stopping olanzapine 3. The risk exists with all antipsychotic agents, though atypical antipsychotics like olanzapine carry lower risk than traditional neuroleptics 2.
Respiratory Depression with Benzodiazepines
Critical warning: Fatalities have been reported with concurrent use of benzodiazepines and high-dose olanzapine 1. There is significant risk of oversedation and respiratory depression when combining these medications.
Cardiovascular Effects
- Orthostatic hypotension with associated dizziness, tachycardia, bradycardia, and syncope, especially during initial dose titration 3
- QTc prolongation has been associated with atypical antipsychotics, though generally not clinically significant 2
- Increased risk of stroke or transient ischemic attacks in elderly patients with dementia-related psychosis 3
Metabolic Complications
Hyperglycemia and Diabetes
Extreme hyperglycemia associated with ketoacidosis, hyperosmolar coma, or death has been reported 3. Patients require:
- Fasting blood glucose testing at baseline and periodically during treatment
- Monitoring for symptoms of hyperglycemia 3
A case report documented diabetic ketoacidosis in a 16-year-old girl during olanzapine therapy 5.
Weight Gain
Weight gain can be extreme and represents the most common significant problem with atypical antipsychotics 2. Regular weight monitoring is essential, with checks recommended weekly for 6 weeks, then at 3 months and annually 4.
Dyslipidemia
Undesirable alterations in lipids require fasting lipid testing at baseline and periodically during treatment 3.
Neurological Side Effects
While olanzapine has lower risk than traditional antipsychotics, extrapyramidal symptoms can still occur:
- Extrapyramidal symptoms - observed in 27% of patients receiving high-dose olanzapine 6
- Akathisia - may require dose reduction or switch to quetiapine 4
- Seizures - use cautiously in patients with history of seizures or conditions that lower seizure threshold 3
Hematological Effects
Although primarily associated with clozapine, agranulocytosis can occur with any antipsychotic agent including olanzapine 2. Patients with history of clinically significant low white blood cell count require frequent CBC monitoring during the first months of therapy 3.
Hepatic Effects
Transient, non-dose-dependent, asymptomatic elevations in liver enzymes have been noted 7, 8. Two cases of liver enzyme abnormalities with fatty infiltrates associated with obesity were reported in adolescent males 2.
Special Populations
Adolescents
Teenagers experience greater increases in 3:
- Prolactin levels
- Liver enzymes
- Sedation compared with adults
Elderly with Dementia
Black box warning: Increased risk of death and cerebrovascular adverse events 3. Olanzapine is not approved for dementia-related psychosis.
Dose-Related Considerations
A study of high-dose olanzapine (45-160 mg daily) found 6:
- Extrapyramidal symptoms: 27%
- Sedation: 25%
- Weight gain: 14%
- Neuroleptic malignant syndrome: 2%
- QTc prolongation: 1%
- Two deaths where olanzapine was a possible contributing cause
Monitoring Requirements
Before starting and periodically during treatment, obtain 4:
- BMI and waist circumference (weekly for 6 weeks initially)
- Blood pressure
- Fasting glucose (recheck at 4 weeks)
- HbA1c
- Lipid profile
- Prolactin
- Liver function tests
- Electrocardiogram
- Complete blood count
Key Clinical Pitfalls
Never combine olanzapine with benzodiazepines without extreme caution due to fatal respiratory depression risk 1. Reduce doses in older patients and those with hepatic impairment 1. The cognitive and motor impairment potential requires caution when operating machinery 3. Despite side effects, olanzapine demonstrates superior efficacy compared to haloperidol and comparable or superior efficacy to risperidone for negative and depressive symptoms 9.